• 제목/요약/키워드: polycystic ovary

검색결과 138건 처리시간 0.034초

홍삼사포닌 투여의 다낭성난소에 의한 불임 치료효과 및 기작연구 (Studies on the Therapeutic Effect and Mechanism of Korean Red Ginseng Total Saponin on Infertility Caused by Polycystic Ovaries)

  • 김세은;오동민;심경미;정문진;임성철;나승열;이윤렬;강성수;문창종;김종춘;김성호;배춘식
    • Applied Microscopy
    • /
    • 제39권1호
    • /
    • pp.1-7
    • /
    • 2009
  • 사람에서의 PCO와 몇몇 측면에서 유사한, 실험적으로 유발된 다낭성난소(polycystic ovary, PCO)는 장기간 작용하는 estradiol valerate (EV)에 의해 유발된다. 랫드에서 스테로이드로 유발한 PCO 모델에서 홍삼 총사포닌의 역할에 대한 우리의 이전연구는 전침이 난소의 nerve growth factor (NGF) 농도를 조절하는 것을 검증하였다. 실제로 PCO와 관련된 난소 기능부전의 병리기전에서 신경성 요소의 관련성은 난소로의 교감신경유출(sympathetic outflow)의 증가로 인해 높아진다. 따라서 본 연구에서는 치료제로서의 GTS 투여가 PCO를 유발한 랫드에서 교감신경 활성을 조절할 것이라는 가설을 시험해보고자 하였다. 본 연구에서는 스테로이드로 유발한 PCO에 내재하고 있는 병태생리학적 과정과 연관된 NGF 단백질과 NGF mRNA를 분석함으로써 이루어졌다. PCO가 유발된 랫드에서 EV 대조군은 oil 대조군과 비교하였을 때 유의적으로 높은 NGF mRNA의 발현을 나타내었으며, GTS 투여군은 EV 대조군에 비해 유의적으로 낮은 NGF mRNA의 발현을 나타내었다. 그러나 NGF 단백질은 oil 대조군에 비해 EV 대조군과 GTS 투여군에서도 유의적인 변화를 발견할 수 없었다. 이러한 결과는 EV가 설치류에서 낭종 형성과 무배란을 유발하는 병리학적 단계의 구성요소일 수 있는 난소의 신경향성 단계(neurotrophic state)를 조절한다고 생각할 수 있다.

여성 불임환자 30례의 임상결과보고 (Case Reports of 30 Female Infertility)

  • 김미선
    • 대한한방부인과학회지
    • /
    • 제30권3호
    • /
    • pp.128-135
    • /
    • 2017
  • Objectives: This study is to report the effects of acupuncture, moxibustion and herbal medicine on infertility. Methods: From February 2015 to December 2016, 44 women with infertility were treated with acupuncture, moxibustion and herbal medicine. 6 months later, follow up and analysis were performed. Results: Of the total 44 women, 19 were successful in pregnancy. Of the 30 women who were contacted by follow-up after 6 months, 19 (63.3%) were successful in pregnancy. 6 of the 8 women who had abortion experience and 5 of the 6 women without the symptoms were pregnant. And 2 with dysmenorrhea, women with follicular development failure, hydrosalpinx, ectopic pregnancy, anovulatory infertility patients, polycystic ovary syndrome were all successfully pregnant. Conclusions: This study suggests that acupuncture, moxibustion and herbal medicine are useful and shows possibility to increasing pregnancy rates.

이차성 비만의 진단 (Evaluation of Secondary Obesity)

  • 김보연
    • 비만대사연구학술지
    • /
    • 제1권2호
    • /
    • pp.53-58
    • /
    • 2022
  • While the rising epidemic of obesity is primarily attributed to a sedentary lifestyle, poor dietary habits, and the aging of the population, secondary causes of obesity generally go undetected and untreated. These include endocrinological disorders, such as Cushing's syndrome, polycystic ovary syndrome, hypothalamic obesity, hypogonadism, and hypothyroidism, as well as genetic, syndromic, and drug-related obesity. We present an overview of the major disorders associated with obesity, highlighting the pathophysiologic mechanisms and discussing the diagnostic and treatment strategies that are most helpful to practicing physicians in recognizing and treating these generally under-detected and undertreated disorders.

Endocrine comorbidities of pediatric obesity

  • Lee, Jieun;Kim, Jae Hyun
    • Clinical and Experimental Pediatrics
    • /
    • 제64권12호
    • /
    • pp.619-627
    • /
    • 2021
  • Pediatric obesity has become a serious public health issue. The prevalence of obesity in children and adolescents has increased worldwide and in Korea over several decades. Obese children are more likely to be obese adults with an increased cardiovascular risk. Therefore, maintaining a healthy weight and preventing obesity during childhood are of critical importance. Moreover, obese children and adolescents often have endocrine comorbidities such as prediabetes, type 2 diabetes, dyslipidemia, metabolic syndrome, polycystic ovary syndrome, and central precocious puberty. Hence, the early implementation of obesity management using a multidisciplinary team approach and screening for these comorbidities in obese children and adolescents are required with the appropriate management of each comorbidity and/or specialist referral.

Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review

  • Yoojin Lindsey Chung
    • Journal of Yeungnam Medical Science
    • /
    • 제41권3호
    • /
    • pp.158-165
    • /
    • 2024
  • Over the past few decades, there has been a notable increase in the incidence of pediatric obesity, which is a significant public health concern. Children who are obese have a greater risk of type 2 diabetes, hypertension, dyslipidemia, polycystic ovary syndrome, obstructive sleep apnea, and adult obesity. Lifestyle modification therapy is typically the initial approach to treat pediatric obesity. For patients who do not achieve success with lifestyle modification therapy alone, pharmacotherapy is the next logical treatment option. When selecting an anti-obesity medication (AOM), it is essential to first ascertain the medical background of the patient, including current medications and obesity-associated comorbidities. Evaluation of obesity phenotypes in patients may also be beneficial. AOMs for pediatric obesity include metformin, orlistat, glucagon-like peptide 1 agonists, phentermine, and the phentermine/topiramate combination. Sufficient lifestyle modification therapy should be administered before considering pharmacotherapy and continued after the initiation of AOM. To ensure healthy development, monitoring growth and puberty development during anti-obesity treatments is essential.